Florence Roufosse
YOU?
Author Swipe
View article: Efficacité à 2 ans des traitements anti-IL-5/IL-5R chez les patients atteints de Granulomatose Éosinophilique avec Polyangéite selon les antécédents de sévérité de la maladie
Efficacité à 2 ans des traitements anti-IL-5/IL-5R chez les patients atteints de Granulomatose Éosinophilique avec Polyangéite selon les antécédents de sévérité de la maladie Open
View article: The Effect of Benralizumab and Mepolizumab on Use of Oral Glucocorticoids in Patients With Eosinophilic Granulomatosis With Polyangiitis
The Effect of Benralizumab and Mepolizumab on Use of Oral Glucocorticoids in Patients With Eosinophilic Granulomatosis With Polyangiitis Open
Objective The phase 3 MANDARA study demonstrated noninferiority of benralizumab versus mepolizumab for remission in patients with eosinophilic granulomatosis with polyangiitis (EGPA). More benralizumab‐treated patients achieved complete wi…
View article: Clinical value at baseline and follow-up of myeloperoxidase-antibodies in ANCA-associated vasculitis
Clinical value at baseline and follow-up of myeloperoxidase-antibodies in ANCA-associated vasculitis Open
Background ANCA-associated vasculitides (AAV) are potentially organ- or life-threatening disorders that can cause irreversible damage if treatment is not started in time. The course of the disease may vary once remission has been achieved,…
View article: Two-year efficacy and safety of anti-interleukin-5/receptor therapy for eosinophilic granulomatosis with polyangiitis
Two-year efficacy and safety of anti-interleukin-5/receptor therapy for eosinophilic granulomatosis with polyangiitis Open
In patients with EGPA, treatment for 2 years with anti-IL-5/R therapies is associated with durable rates of remission, discontinuation of OGCs, bEOS depletion, and low relapse rates. Switching from mepolizumab to benralizumab enhances bEOS…
View article: OP0166 EFFICACY AND SAFETY OF TWO YEARS OF TREATMENT WITH ANTI-IL-5/R THERAPIES FOR EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS
OP0166 EFFICACY AND SAFETY OF TWO YEARS OF TREATMENT WITH ANTI-IL-5/R THERAPIES FOR EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS Open
View article: POS0327 EFFICACY OF TWO YEARS OF TREATMENT WITH ANTI-IL-5/R THERAPIES ACCORDING TO HISTORIC DISEASE SEVERITY IN PATIENTS WITH EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS
POS0327 EFFICACY OF TWO YEARS OF TREATMENT WITH ANTI-IL-5/R THERAPIES ACCORDING TO HISTORIC DISEASE SEVERITY IN PATIENTS WITH EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS Open
View article: Canakinumab treatment patterns in sJIA, FMF, TRAPS, and MKD/HIDS: real-world insights from a Belgian non-interventional study
Canakinumab treatment patterns in sJIA, FMF, TRAPS, and MKD/HIDS: real-world insights from a Belgian non-interventional study Open
View article: Mepolizumab in patients with lymphoid-variant hypereosinophilic syndrome: A multicenter prospective study
Mepolizumab in patients with lymphoid-variant hypereosinophilic syndrome: A multicenter prospective study Open
View article: Interleukin‐5 as a pleiotropic cytokine orchestrating airway type 2 inflammation: Effects on and beyond eosinophils
Interleukin‐5 as a pleiotropic cytokine orchestrating airway type 2 inflammation: Effects on and beyond eosinophils Open
Interleukin (IL)‐5 is the key cytokine in the maturation, activation, proliferation, migration and survival of eosinophils, which are key effector cells in many upper and lower airway diseases. Through its effects on eosinophils, IL‐5 indi…
View article: Hypereosinophilic syndrome response to mepolizumab in the setting of a compassionate use program
Hypereosinophilic syndrome response to mepolizumab in the setting of a compassionate use program Open
Mepolizumab, an anti-interleukin-5 antibody, has been proven a safe and effective glucocorticoid (GC)-sparing drug for many patients with nonclonal hypereosinophilic syndrome (HES) and is now approved in many countries. It remains unclear,…
View article: Biologic therapy in rare eosinophil-associated disorders: remaining questions and translational research opportunities
Biologic therapy in rare eosinophil-associated disorders: remaining questions and translational research opportunities Open
Rare eosinophil-associated disorders (EADs), including hypereosinophilic syndrome, eosinophilic granulomatosis with polyangiitis, and eosinophilic gastrointestinal disorders, are a heterogeneous group of conditions characterized by blood a…
View article: Benralizumab versus Mepolizumab for Eosinophilic Granulomatosis with Polyangiitis
Benralizumab versus Mepolizumab for Eosinophilic Granulomatosis with Polyangiitis Open
Benralizumab was noninferior to mepolizumab for the induction of remission in patients with relapsing or refractory EGPA. (Funded by AstraZeneca; MANDARA ClinicalTrials.gov number, NCT04157348.).
View article: Efficacy and Safety of Benralizumab Compared with Mepolizumab in the Treatment of Eosinophilic Granulomatosis with Polyangiitis in Patients Receiving Standard of Care Therapy: Phase 3 MANDARA Study
Efficacy and Safety of Benralizumab Compared with Mepolizumab in the Treatment of Eosinophilic Granulomatosis with Polyangiitis in Patients Receiving Standard of Care Therapy: Phase 3 MANDARA Study Open
View article: Case report: Serious unexpected vascular events in two patients with lymphocytic variant hypereosinophilic syndrome
Case report: Serious unexpected vascular events in two patients with lymphocytic variant hypereosinophilic syndrome Open
Background Lymphocytic-variant hypereosinophilic syndrome (L-HES) is a form of reactive hypereosinophilia, most commonly associated with interleukin-5 over-production by clonal, most commonly CD3 − CD4 + CD2 hi CD5 hi CD45RO + T-cells. Pat…
View article: PB2229: A PHASE 3 STUDY EVALUATING THE EFFICACY AND SAFETY OF BENRALIZUMAB IN PATIENTS WITH HYPEREOSINOPHILIC SYNDROME
PB2229: A PHASE 3 STUDY EVALUATING THE EFFICACY AND SAFETY OF BENRALIZUMAB IN PATIENTS WITH HYPEREOSINOPHILIC SYNDROME Open
Topic: 16. Myeloproliferative neoplasms - Clinical Background: Hypereosinophilic syndromes (HES) are rare and heterogenous disorders characterized by persistent blood eosinophilia (absolute eosinophil count [AEC] >1500 cells/μL) and eosino…
View article: HES and EGPA
HES and EGPA Open
Elevated eosinophil counts are implicated in multiple diseases, from relatively prevalent organ-specific disorders such as severe eosinophilic asthma, to rare multisystem disorders such as hypereosinophilic syndrome (HES) and eosinophilic …
View article: Plain Language Summary of principles for improving the care of people with eosinophil-associated diseases
Plain Language Summary of principles for improving the care of people with eosinophil-associated diseases Open
Eosinophil-associated diseases (EADs) are a group of conditions in which eosinophils (a type of white blood cell) are thought to play a key role in the disease and how it develops. Some EADs are common, such as atopic dermatitis (also call…
View article: Unmet needs and evidence gaps in hypereosinophilic syndrome and eosinophilic granulomatosis with polyangiitis
Unmet needs and evidence gaps in hypereosinophilic syndrome and eosinophilic granulomatosis with polyangiitis Open
View article: Mepolizumab therapy improves the most bothersome symptoms in patients with hypereosinophilic syndrome
Mepolizumab therapy improves the most bothersome symptoms in patients with hypereosinophilic syndrome Open
Background Hypereosinophilic syndrome (HES) is characterized by persistent elevated blood and/or tissue eosinophil levels and eosinophil-mediated organ damage. Presentation is highly heterogenous; patients may experience symptoms affecting…
View article: Proposed refined diagnostic criteria and classification of eosinophil disorders and related syndromes
Proposed refined diagnostic criteria and classification of eosinophil disorders and related syndromes Open
Eosinophilia and eosinophil activation are recurrent features in various reactive states and certain hematologic malignancies. In patients with hypereosinophilia (HE), HE‐induced organ damage is often encountered and may lead to the diagno…
View article: Mepolizumab Reduces Hypereosinophilic Syndrome Flares Irrespective of Blood Eosinophil Count and Interleukin-5
Mepolizumab Reduces Hypereosinophilic Syndrome Flares Irrespective of Blood Eosinophil Count and Interleukin-5 Open
Mepolizumab was efficacious in the patients with HES studied, irrespective of baseline BEC. Undetectable IL-5 levels should not preclude mepolizumab treatment.
View article: Improving Care in Eosinophil-Associated Diseases: A Charter
Improving Care in Eosinophil-Associated Diseases: A Charter Open
View article: An International, Retrospective Study of Off-Label Biologic Use in the Treatment of Hypereosinophilic Syndromes
An International, Retrospective Study of Off-Label Biologic Use in the Treatment of Hypereosinophilic Syndromes Open
View article: Eosinophils and eosinophilic immune dysfunction in health and disease
Eosinophils and eosinophilic immune dysfunction in health and disease Open
The functions ascribed to eosinophils have classically been limited to host defence against certain parasitic infections and potentially deleterious effects in the setting of specific diseases that are associated with elevated eosinophil c…
View article: Insights from Social Media on the Patient Experience of Living With Rare Eosinophil-Driven Diseases
Insights from Social Media on the Patient Experience of Living With Rare Eosinophil-Driven Diseases Open
Eosinophilic granulomatosis with polyangiitis (EGPA) and hypereosinophilic syndrome (HES) are driven by persistently high eosinophil numbers, causing damage to tissues and organs. As rare diseases, they are often underappreciated by health…
View article: Hypereosinophilic syndromes and lung involvement
Hypereosinophilic syndromes and lung involvement Open
HES are a heterogeneous group of rare disorders characterised by hypereosinophilia and eosinophil-mediated organ damage and/or dysfunction. Although specific disease variants primarily involving myeloid or lymphoid cells exist, underlying …
View article: Future prospects of translational and clinical eosinophil research
Future prospects of translational and clinical eosinophil research Open
Eosinophils have long been known to contribute to various airway, interstitial and vascular lung diseases. These cells are built to destroy large extracellular helminths, and are loaded with toxic mediators and enzymes to do so. Not surpri…
View article: From DREAM to REALITI‐A and beyond: Mepolizumab for the treatment of eosinophil‐driven diseases
From DREAM to REALITI‐A and beyond: Mepolizumab for the treatment of eosinophil‐driven diseases Open
Effective treatment of inflammatory diseases is often challenging owing to their heterogeneous pathophysiology. Understanding of the underlying disease mechanisms is improving and it is now clear that eosinophils play a complex pathophysio…
View article: Safety and Efficacy of Mepolizumab in Hypereosinophilic Syndrome: An Open-Label Extension Study
Safety and Efficacy of Mepolizumab in Hypereosinophilic Syndrome: An Open-Label Extension Study Open
View article: Safety and Efficacy of Mepolizumab in Hypereosinophilic Syndrome: An Open-Label Extension Study
Safety and Efficacy of Mepolizumab in Hypereosinophilic Syndrome: An Open-Label Extension Study Open